Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Natalizumab versus Fingolimod on CNS Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis
2013-004622-29Phase 4Completed
- Sponsor
- Biogen
- Start
- Aug 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in multiple sclerosis (MS) comparing Natalizumab arm with Fingolimod arm (2 arms). Started Aug 2014; status: completed.
02
Drugs
natalizumabfingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-004622-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004622-29.